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Highlights 
 Validated a statistical model to project lung cancer mortality rates to 2040. 
 Lung cancer mortality rates are expected to continually decline in Australia. 
 Number of lung cancer deaths will continue to be substantial and to increase. 
 These results will inform planning to meet future health service needs. 
 Projected rates can serve as a benchmark for tobacco control in Australia. 
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Abstract 
Objectives 
The aim was to develop and validate a statistical model which uses past trends for lung 
cancer mortality and historical and current data on tobacco consumption to project lung 
cancer mortality rates into the future for Australia.  
Methods 
We used generalized linear models (GLMs) with Poisson distribution including either age, 
birth cohort or period, and/or various measures of population tobacco exposure 
(considering cross-sectional smoking prevalence, cigarettes smoked and tar exposure per 
capita). Sex-specific models were fitted to data for 1956-2015 and age-standardized lung 
cancer mortality rates were projected forward to 2040. Possible lags of 20-30 years between 
tobacco exposure and lung cancer mortality were examined. The best model was selected 
using analysis of deviance. To validate the selected model, we temporarily re-fitted it to 
data for 1956-1990 and compared the projected rates to 2015 with the observed rates for 
1991-2015. 
Results 
The best fitting model used information on age, birth cohort and tar exposure per capita; 
close concordance with the observed data was achieved in the validation. The forward 
projections for lung cancer mortality using this model indicate that male and female age-
standardized rates will decline over the period 2011-2015 to 2036-2040 from 27.2 to 15.1 
per 100,000, and 15.8 to 11.8 per 100,000, respectively. However, due to population growth 
and ageing the number of deaths will increase by 7.9% for males and 57.9% for females; 
from 41,040 (24,831 males, 16,209 females) in 2011-2015 to 52,403 (26,805 males, 25,598 
females) in 2036-2040.  
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Conclusion 
In the context of the mature tobacco epidemic with past peaks in tobacco consumption for 
both males and females, lung cancer mortality rates are expected to continually decline 
over the next 25 years. However, the number of lung cancer deaths will continue to be 
substantial, and to increase, in Australia’s ageing population. 
 
Keywords: lung cancer mortality; statistical projections; Australia; tobacco consumption; 
generalized linear models; cohort effect; population-based; health service planning; tobacco 
epidemic 
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1. Introduction 
Lung cancer has been the most common cause of cancer death over the last five decades in 
Australia[1]. Evidence of a strong causal association between tobacco smoking and lung 
cancer has been well established since the early 1950s [2]. Australia has successfully 
implemented many tobacco control interventions, and there have been subsequent 
reductions in lung cancer mortality [3]. However, despite the marked decline in smoking 
prevalence seen for Australian males since the 1950s and Australian females since the 1980s 
[3], it is still estimated that lung cancer will be the largest cause of cancer death in 2017 [4].  
 
Cancer mortality is an important measure of the burden of cancer in a population, and can 
be of great use in informing the planning of health services and resource management [5, 6]. 
As tobacco exposure is the most significant risk factor for lung cancer [2], it is well accepted 
that it is an important explanatory factor for lung cancer mortality [6, 7]. The projected 
impact of tobacco control policies on future lung cancer mortality rates is crucial to 
understanding the success of such policies [5, 7]. However, lung cancer mortality projections 
have commonly been based solely on past mortality trends, due to the scarcity of data on 
historical smoking behaviour at the population level [8]. Currently, the most common 
method for projecting cancer incidence and mortality is to use age-period-cohort (APC) 
models. The basis of APC models is well explained in the published literature [9, 10], but in 
brief, APC models describe the rate of an event as a function of age, period and cohort 
effects. There is, however, a non-identifiability problem inherent in APC models due to the 
linear relationship between age, period and cohort [9]. While there have been some 
developments in methods to overcome the non-identifiability problem [10-16], there is no 
way to distinguish the period effect and the cohort effect, and the parameter estimates 
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obtained can be sensitive to the choice of constraints placed on the period and cohort 
factors [6, 17].  
 
Some previous studies have reported the inclusion of detailed smoking data as a factor in 
lung cancer mortality projections [6, 7, 18, 19]. Brown and Kessler (1988)[6] using data for 
the United States of America (USA) and Shibuya et al., (2005)[7] using data for Australia, 
USA, United Kingdom and Canada, fitted a Generalized Linear Model (GLM) using Poisson 
regression for lung cancer mortality rates with terms for age, cohort and lagged sex-period-
specific cigarette tar consumption [6, 7]. One other study by Preston et al. (2014) used a log-
linear binomial regression model for lung cancer mortality rates in the USA with terms for 
age and number of years of smoking prior to age 40 [18], and a study using Spanish data by 
Martin-Sanchez et al., (2017) used a linear regression model to predict lung cancer mortality 
rates based on smoking prevalence for two large age groups [19]. Here, we propose an 
alternative model to project lung cancer mortality rates using GLMs with a Poisson 
distribution including age and cohort, or age and period, together with sex-age-cohort-
specific smoking-related variables. As with the methods used by Brown and Kessler (1988) 
[6], Shibuya et al. (2005) [7], and Preston et al. (2014) [18], our model does not suffer the 
non-identifiability problem. With this model, we are also able to examine the period or 
cohort effect after adjusting for smoking-related variables. 
 
Due to delays in the impact of changes in smoking behaviour, lung cancer mortality rates to 
2040 are expected to predominantly reflect tobacco exposure that has already occurred. 
The aim of this study was therefore to develop and validate a statistical model to project 
age-standardized lung cancer mortality rates and numbers of deaths from lung cancer for 
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the period 2016 to 2040, based on past trends in lung cancer mortality and historical and 
current data on tobacco consumption for the Australian population.  
 
2. Material and Methods 
2.1. Data sources 
2.1.1 Lung cancer mortality and population data 
We obtained from the World Health Organization (WHO) Mortality Database (MDB) [20], 
national tabulated data on the numbers of deaths from lung cancer in Australia by sex, age 
and calendar year from 1956 to 2015 to allow for a minimum of 20 years of observed data 
before the peak in lung cancer mortality rates for males was reached in the early 1980s. The 
data available in the WHO MDB comprise deaths registered in national vital registration 
systems with underlying cause of death as coded by the relevant national authority in each 
country. Australia is one of the countries with near complete population coverage [20]. In 
Australia, it is a legal requirement for each state and territory to record all deaths in 
registries administered by the various state and territory Registrars of Births, Deaths and 
Marriages, and either a medical practitioner or a coroner is required to certify the cause of 
death [21]. The corresponding Australian population data by sex, 5-year age group and 
calendar year from 1956 to 2040 were obtained from the Australian Historical Population 
Statistics and Population Projections (Series B, based on medium population growth) 
produced by the Australian Bureau of Statistics (ABS) [22, 23]. For the purposes of our 
analyses, we grouped the mortality data into 5-year age groups and 5-year periods. Deaths 
from lung cancer that occurred before the age of 30 were excluded, as death from lung 
cancer is rare for this age group [1]. 
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2.1.2. Data on smoking patterns in Australia 
We obtained the data on smoking from two data sources: the International Smoking 
Statistics (ISS) Web Edition [24], and the National Drug Strategy Household Surveys (NDSHS) 
for 2007-2016 [25-28]. Integrated ISS and newly released NDSHS data are hereafter referred 
to as “ISS-NDSHS data”. As data on smoking behaviour for pre-adolescents and young 
adolescents is very scarce, and is not included in the sales adjustment calculations in the ISS, 
we did not include smoking information for those under 15 years of age. Although smoking 
clearly does occur below this age, it is at a much lower level than for the adult population 
[25-28]. 
 
ISS data 
The ISS database provides data from different surveys, and provides information on annual 
tobacco sales from 1920 to 2010, smoking prevalence by age group and sex from 1945 to 
2004, and number of cigarettes consumed per person per day by age group and sex from 
1972 to 2004 [24]. Data for men and women from nationally representative surveys were 
separately included. When multiple surveys were available, a priori defined selection criteria 
(as described in Appendix 1) were applied to determine which data sources to include in the 
current analysis for each calendar year.  
 
NDSHS data 
The NDSHS is one of the national surveys included in the ISS up to 2004, and has been 
conducted at three yearly intervals since 1985 [24]. The newly released NDSHS data for 
2007- 2016 were processed using the same methods previously described for the ISS data 
[24] to extend the smoking prevalence and tobacco consumption data to 2016. The 
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Absolute Person Weight was used in the calculation of the smoking statistics to ensure that 
the sample is representative of the population [27]. 
 
2.2. Outcome and study variables 
The outcomes of interest were the lung cancer mortality rate and the number of deaths 
from lung cancer by 5-year calendar period for men and women. Study variables used in this 
analysis included sex, 5-year age group, 5-year calendar period and 5-year birth cohorts, 
which were coded as the middle year of each five year period. Person-years at risk were 
approximated by the population estimates for the middle year of the five year period [6]. 
Several smoking-related variables were considered, including the smoking prevalence, 
number of cigarettes sold, number of cigarettes consumed per capita, and average tar per 
cigarette. Previous research has suggested that there is a considerable lag between the 
initiation of smoking and the development of lung cancer [29], but that this lag may vary 
considerably across populations and countries [6, 7, 30-33]. In this study, all sex-specific 
smoking-related variables were lagged by 20-30 years in each model for males and females 
separately. In order to allow for a 30-year lag, all smoking-related variables were 
reconstructed backwards to 1930 and projected forwards to 2020, and were aggregated 
into 5-year periods. Similar backward reconstruction techniques were used by Adair et al. 
and Shibuya et al. to estimate tobacco consumption data [3, 7]. The data sources and the 
estimation process for each smoking-related variable are summarised and described in 
detail in Appendix 2. 
 
2.3. Statistical analyses 
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Given the inherent non-identifiability problem in APC models due to the linear relationship 
between age, period and cohort [9], additional strategies are required to deal with this, and 
so these models need to be implemented using special software packages which often don’t 
allow the user to modify the prediction of future cohort and period effects. We therefore 
chose to use GLMs with a Poisson distribution including age, birth cohort and smoking-
related variables, or age, period and one or more different smoking-related variables. 
Possible lags of 20-30 years between cigarette tar exposure and lung cancer mortality were 
examined for each GLM fitted model. To assess the best model for each sex with different 
smoking-related variable(s), we compared the fit of various models to data for 1956-2015 
using analysis of deviance [6, 34]. The best fitting model was selected on the basis of 
minimising the deviance as a measure of goodness-of-fit [6], and the best smoking-related 
variable to predict lung cancer mortality was found to be the sex-age-specific cigarette tar 
exposure with a lag of 26 years for males and 29 years for females. Consistent with previous 
studies, we confirmed that the cohort effect is a stronger predictor than the period effect 
for lung cancer mortality projections, as cohort effects reflect changes in early life exposure 
to risk factors such as smoking [6, 7, 35]. Our final model can be presented as a 
parsimonious equation: 
𝑙𝑛𝐷𝑖𝑗 = 𝑙𝑛𝑁𝑖𝑗 + 𝛼𝐴𝑔𝑒𝑖 + 𝛽𝐶𝑇𝐶𝑖𝑗−𝐿 + 𝛾𝐶𝑜ℎ𝑜𝑟𝑡𝑙−𝑖+𝑗 + 𝜀𝑖𝑗 
where 𝐷𝑖𝑗 and 𝑁𝑖𝑗 denote the number of deaths from lung cancer and the number at risk in 
the population for the ith age group during jth calendar period; 𝐴𝑔𝑒𝑖  denotes the age group 
30-34, 35-39, …, ≥85 years, and 𝐶𝑜ℎ𝑜𝑟𝑡𝑙−𝑖+𝑗 denotes the birth cohorts 1875-1879, 1880-
1884, …, 1980-1984;  𝐶𝑇𝐶𝑖𝑗−𝐿 denotes the cigarette tar exposure for the population in the i
th 
age group during j-Lth calendar period, which is lagged by L years (26 years for males and 29 
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years for females). The characteristics of different models using standard GLMs are 
summarized in Appendix 3. 
 
To validate the selected projection model, we fitted the model to the data for 1956-1990 
and then projected forward to 2015. We then compared the predicted lung cancer mortality 
from the model for the period 1991-2015 with the actual observed data for the period. 
Confidence intervals and statistical significance of standardized mortality rate ratios of the 
observed and predicted mortality rates were calculated using formulae from Boyle and 
Parkin [36]. Comparisons of our final model with an age-cohort model and age-cigarette tar 
exposure model which excluded a cohort effect, fitted using the standard GLM, are shown in 
Appendix 4. We also compared these models with an APC model fitted by the apcspline 
command in Stata 13 [13] with natural cubic splines for smoothing. Details of the methods 
used by the apcspline command are provided elsewhere [13]. Briefly, we compared a 
number of APC models with different numbers of knots for the age, period and cohort 
effects to identify the one with the lowest Bayesian information criterion (BIC). We applied a 
default damping factor (0.92) to the drift when projecting rates to the future, and future 
period and cohort effects were assumed to be the same as those for the most recent 
observed period and cohort [13]. 
 
To project lung cancer mortality beyond the observed calendar period, we assumed that the 
age effect remained unchanged over time and reflects the general level of lung cancer risk 
in the non-smoking population [6, 7]. The cohort effect is considered to be a reflection of 
many cohort-specific smoking characteristics, but unfortunately not all were available for 
this study. We tested the variation in the cohort parameters explained by each cohort-
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specific smoking characteristic using linear regression. We found that cohort-specific 
cigarette tar exposure was the best predictor for the cohort effects compared to the other 
smoking-related variables considered for inclusion in the model, and so we used cigarette 
tar exposure per capita to estimate future cohort parameters. We also assumed that other 
relevant factors which can be attributed to period effects will remain constant over time, 
such as environmental, occupational, cancer diagnosis and treatment factors. All age-
standardized lung cancer mortality rates presented in this paper were standardized to the 
WHO World Standard Population [37]. 
 
We also conducted sensitivity analyses by fitting the projection models under the 
assumption that there had been no change in tar content since 1995 and also by using 
different backwards estimated cigarette consumption data. A parametric bootstrap 
simulation technique was used to compute 95% prediction intervals for model coefficients. 
All statistical analyses were performed using Stata  (version 13.1, STATA Corporation, 
College Station, TX). 
  
3. Results 
Figure 1 shows smoking prevalence, the annual number of cigarettes smoked per capita, 
and annual cigarette tar exposure (g) per capita by sex and calendar period for the 
Australian population aged 15 years or above. For males, the smoking prevalence has 
decreased since around the 1950s, prior to which rates were fairly stable from around 1930. 
The other measures of exposure, the number of cigarettes smoked per capita and the 
annual tar exposure per capita, have been declining from peaks in the early 1960s and late 
1950s, respectively, after prior increasing trends. The trend for females in both smoking 
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prevalence and number of cigarettes smoked has been one of gradual increase towards 
their peaks around the 1980s which were later than for males, followed thereafter by a 
decline. Unlike the other two exposure variables, the decline in cigarette tar exposure per 
capita for females is similar in timing to that for males, but at a much slower pace until the 
mid-1980s. In the past, females had lower exposure according to all measures compared to 
males in the same calendar year, but projected values show that the exposure by sex, for 
each measure, is expected to converge around the year 2020. Given the significant 
reduction in both tobacco consumption and average tar content of cigarettes (which 
between 1980 and 1994 dropped from 13.2 to 6.4 mg per cigarette, and is estimated to 
have reached 5.3 mg per cigarette in 2000), for both males and females, the decline in 
cigarette tar exposure (Figure 1 C) occurred at a much faster pace than for the other two 
measures (Figure 1 A and B) and reached very low levels in the early 2000s. 
 
Figure 2 shows the smoking prevalence, the number of cigarettes smoked and tar exposure 
by birth cohort and age. For males, the overall peak in number of cigarettes smoked and 
cigarette tar exposure occurred at age 35-45 for cohorts born in the 1910s and 1930s and 
the prevalence of smoking was also greatest for earlier birth cohorts (back to the 1900s), 
while for females the overall peaks in number of cigarettes smoked and smoking prevalence 
appear to occur at a younger age (25-40 years) for more recent cohorts, born around the 
1950s to 1970s, but the peak in cigarette tar exposure appears to have occurred for earlier 
cohorts at older age (35-45 years). 
 
The 25-year validation of the final models was based on the observed mortality data from 
1956 to 1990 with cigarette tar exposure data lagged by 26 years for males and 29 years for 
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females, projected to 2015. Figure 3 shows the comparison of the predicted and observed 
age-standardized lung cancer mortality rates in 1991-2015. The fitted rates for 1956-1990 
and the projected rates for 1991-2015 for both males and females are close to the observed 
values, with no significant differences observed, suggesting that the model appears to 
provide valid projections of lung cancer mortality in Australia. The sensitivity analyses that 
were conducted by applying constant average tar content per cigarette for 1994 into the 
future and using different backwards estimated cigarette consumption data resulted in 
minimal change to the projection models (data not shown). 
 
The estimated age and cohort effects and the regression coefficient for cigarette tar 
exposure are shown in Appendix 5. There are strong and significant associations between 
the lung cancer mortality rate and all three of age, cohort, and lagged tar exposure. The 
slope of the sex-age-specific tar exposure differs by sex, with a larger slope for females than 
for males (estimated coefficient for males: 0.0032, 95% CI: 0.0028-0.0036; for females: 
0.0062, 95% CI: 0.0053-0.0072). After adjusting for lagged cigarette tar exposure and age, 
male lung cancer mortality peaked for the cohorts born around the 1910s to 1930s, while 
the female mortality rate peaked for the cohorts born around the 1940s to 1960s.  
 
The observed and predicted age-specific mortality rates are presented in Figure 4 and the 
observed and predicted numbers of deaths from lung cancer and age-standardized lung 
cancer mortality rates are presented in Table 1 and in Figure 5. Both male and female age-
standardized rates are projected to decline over the period 2011-15 to 2036-2040 from 27.2 
to 15.1 per 100,000, and 15.8 to 11.8 per 100,000, respectively. For both males and females, 
the lung cancer mortality rate is consistently low for those aged under 55 years. The 
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mortality rates for all age groups above 54 years declined steadily for males since the 1980s. 
By contrast, for females, a slow decrease in mortality rates was only observed for the 55-64 
and 65-74 years age groups after the 2010s. The mortality rate for females aged ≥75 levelled 
off after 2010 and is predicted to continue at the same level to 2040. Due to population 
growth and ageing the number of deaths will increase by 7.9% for males and 57.9% for 
females; from 41,040 (24,831 males and 16,209 females) in 2011-2015 to 52,403 (26,805 
males and 25,598 females) in 2036-2040. 
 
4. Discussion 
We have developed and validated a flexible model in which predicted future lung cancer 
mortality is a function of age, birth cohort and sex-age-specific per capita cigarette tar 
exposure in the Australian population. Projections for lung cancer mortality based on this 
model indicate that a decreasing trend in the male mortality rate will continue to 2040, and 
that the female mortality rate peaked in 2010. However, the numbers of deaths due to lung 
cancer will increase to 2040, driven by population growth and ageing. Age, birth cohort and 
cigarette tar exposure were found to be the strongest predictors for future lung cancer 
mortality, and the effect of birth cohort and the lag in years between cigarette tar exposure 
and lung cancer mortality appear to differ by sex. Our best-fitting model assumed a lag of 26 
years for males and 29 years for females between tobacco exposure (as measured by 
population average per capita tar exposure) and lung cancer mortality. Unfortunately, this 
considerable lag implies that lung cancer mortality rates in the intermediate term (to 2040), 
cannot be substantially altered via further current initiatives in tobacco control alone, 
although it is very important to note that the benefits of current and new tobacco control 
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policies will be manifest thereafter (estimating these benefits are the subject of our future 
work). 
 
There have been a few previous international studies that have reported statistical 
projection models for lung cancer mortality incorporating smoking-related factors as one of 
the covariates [6, 7, 18, 19, 31]. Only one study (Shibuya et al., 2005) reported long term 
projections of lung cancer mortality using data for the Australian population [7]. Similar to 
the model developed by Brown and Kessler [6], Shibuya and colleagues [7] used GLMs with 
lung cancer mortality data up to 1999 and projected to 2035, and the model was validated 
by excluding the five most recent years of data from the model fitting and comparing the 
predicted rates with those observed. Shibuya et al.’s model was a function of sex-period-
specific cigarette tar exposure. In our model, we identified sex-age-cohort-specific cigarette 
tar exposure as the best predictor among the available smoking-related variables. Our study 
confirmed a significant association between cigarette tar exposure and lung cancer 
mortality rates, and the overall mortality trends were consistent with the projections 
reported by Shibuya et al., with particularly good agreement for the projections for females. 
However, a slightly larger decrease in the lung cancer mortality rate for males was 
suggested by our model, which is a better fit to the observed data than the projections of 
Shibuya et al. Our study also confirmed that smoking prevalence is a poor measure of 
cumulative exposure to tobacco [7]. In addition, consistent with the results of another 
Australian study [3], we observed a slightly shorter lag between tobacco exposure and lung 
cancer mortality for males (26 years) compared to that for females (29 years). This is likely 
because lung cancer mortality is a function of cumulative tobacco exposure, and the level of 
smoking for females is generally lower than for males [3]. 
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Cohort effects are considered to represent risk factors such as smoking behaviour that 
change from generation to generation [10, 18]. Consistent with previous studies, we 
confirmed that the cohort effect is a stronger predictor than the period effect for lung 
cancer mortality projections [6, 7, 30]. Birth cohort is suggested to be a better reflection of 
the number and type of cigarettes a cohort is exposed to when young [38], since smoking 
habits are generally established at an early age and are characteristic for a particular birth 
cohort [39]. Nevertheless, as our model has taken into account detailed data on cigarette 
consumption, the strong cohort effect is likely to also be reflecting changes in smoking 
habits other than cigarette tar exposure from generation to generation [40]. A previous 
study showed that cohort effects in lung cancer are dominated by the number of years 
smoked [18]. This is supported by the differences we observed in projected mortality rates 
for both males and females when applying an age-cohort model to earlier observed data 
without incorporating cigarette tar consumption, compared to our final model incorporating 
both birth cohort and cigarette tar consumption (Appendix 4). We speculate that the cohort 
effect may also reflect other cohort-specific smoking characteristics, such as the type of 
tobacco consumed, duration of smoking, and age of smoking initiation or cessation, as these 
characteristics are all related to birth cohort [18, 41]. In particular, the cessation of smoking 
can reduce the subsequent risk of lung cancer [42], and this is likely to be captured by the 
cohort effect as the population responds to tobacco control interventions over time.  
 
This study has some limitations. The projections in this study involve uncertainties due to 
the variations in data quality between different smoking surveys. Age-specific tobacco 
consumption data were not available prior to 1972 and were backward estimated based on 
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the tobacco sales data and observed consumption data. In addition, data on average tar 
content per cigarette has not been collected in recent years due to uncertainty about the 
accuracy of the standard testing methods. Also, our projection models do not take into 
account other relevant factors which can be attributed to period effects, such as 
environmental and occupational factors, ad hoc lung cancer screening with low dose 
computerised tomography (for smokers – expected to be limited over the period of analysis), 
and changes in cancer treatment, including the introduction of epidermal growth factor 
receptor (EGFR) inhibitors. Previous research suggests that EGFR mutations are more 
common in patients who are non-smokers and patients from Asian backgrounds [43], 
although population level data on EFGR mutations and lung cancer mortality by ethnicity in 
Australia are not available. However, as it is estimated that only 12% of all non-small cell 
lung cancer patients in Australia have EFGR mutations [44], any potential future changes in 
the prevalence and survival patterns for that group should have limited impact on our 
projected estimates. Findings from a large scale cohort study in the USA reported that lung 
cancer mortality rates for non-smokers were stable [45], so we may expect a similar pattern 
in Australia over the period of analysis. Cancer screening and treatment factors were 
unlikely to be relevant for lung cancer mortality in the early years [30], and the relative 
survival rate has remained relatively stable over time [46]. Some other factors, such as 
duration of smoking and the age of smoking initiation, were not included in our models as 
the data are not available for early time periods. Fortunately, these smoking characteristics 
are likely to be captured by the cohort effect, as a previous study reported that the duration 
of smoking, age of smoking initiation and smoking cessation probabilities vary by birth 
cohort [18, 41]. Furthermore, the population denominators were themselves projected by 
the ABS [22, 23], and this adds some uncertainty to our projections. 
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Despite these limitations, this study also has many strengths. First, this study is based on 
long term observed data with high data quality and population coverage [20], and the data 
on deaths from cancer and recorded cause of death have been reported to be very 
complete and have been validated [47]. To ensure the data on smoking patterns are 
representative of the national population, where possible, we have restricted the smoking 
surveys to those conducted at a national level. Second, this is the first study to provide 
validation of projections for 25 years using observed data. Given the 26-29 years lag 
between tobacco exposure and lung cancer mortality, and with the observed tobacco 
consumption data being available until 2016, long term lung cancer mortality projections up 
to 2040 are likely to be reliable. Third, the present models have taken into account detailed 
data on the cigarette tar consumption by calendar period and birth cohort. Our model can 
be implemented using standard GLMs which are commonly available in statistical software 
packages. The advantages of these methods are that the lung cancer mortality rates are 
projected without making strong parametric assumptions to constrain period and cohort 
effects, and they allow the possibility of examining models that include more than one 
smoking-related variable. With the logarithmic link function, the cohort effects can be 
interpreted as relative risks relative to the reference cohort. 
 
The projected decline in lung cancer mortality rates estimated by our study indicates that 
past and current tobacco control interventions implemented in Australia have been 
successful, resulting in continued reductions in lung cancer mortality. However, lung cancer 
mortality rates are still expected to remain at a relatively high level and the estimated 
increase in the actual number of deaths from lung cancer is still substantial. Given that, at a 
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population level, there is a lag of 26-29 years between smoking exposure and lung cancer 
mortality, the effects of newly implemented tobacco control programs may not have a 
significant impact on further reducing lung cancer mortality rates in the short term. This 
means that while the continued reduction in smoking prevalence remains a significant 
public health priority, it is also important that effective lung cancer screening and 
treatments are developed and implemented. Some recent positive developments in lung 
cancer screening and treatment include the validation of a lung cancer risk assessment tool 
to identify high risk individuals for targeted lung cancer screening in a large-scale 
population-based Australian cohort study [48], and that several randomized controlled trials 
in the USA and other countries have shown short term benefits of targeted therapy for lung 
cancer [49-51]. Although the cost-effectiveness of lung cancer screening compared to 
tobacco control programs is still inconclusive [52, 53], the potential benefits of both short 
and long term approaches to reducing lung cancer mortality should be explored. 
 
We found that, not unexpectedly, incorporating tobacco consumption into our model 
considerably improves the accuracy of lung cancer mortality projections. Our best-fitting 
statistical model suggests that mortality rates for both males and females will continue to 
decline over the next 25 years in the context of the mature tobacco epidemic with past 
peaks in tobacco consumption for both males and females, with marked reductions in 
smoking prevalence and cigarette consumption for males since the 1950s and for females 
since the 1980s. However, the number of lung cancer deaths will continue to be substantial, 
and to increase, in Australia’s ageing population. Our estimates of the number of deaths 
from lung cancer in Australia will inform planning to meet future health service needs and 
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these projected rates can serve as a benchmark against which to measure the effect of 
future lung cancer control initiatives in Australia. 
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Figure 1: Estimated smoking prevalence, annual number of cigarettes smoked per capita 
and annual cigarette tar exposure (g) by sex, age group and calendar year, Australia 1930-
2020 
Figure 2: Estimated prevalence of current smokers, annual number of cigarettes smoked, 
and annual cigarette tar exposure (g) per capita by sex, birth cohort and age group 
Figure 3: Validation of 25-year projections using observed data for 1956-1990 projected to 
2015, compared to observed data for 1956-2015 
Figure 4: Observed and predicted age-specific lung cancer mortality rates by age group, 
1956-2040 
Figure 5: Observed and projected numbers of deaths and age-standardized lung cancer 
mortality rates by sex, 1956-2040 
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Table 1: Predicted and observed numbers of deaths from lung cancer and age-standardised 
lung cancer mortality rates* by sex and 5-year period, 1956-2040 
  Number of deaths   
Age-standardised mortality 
rate 
Sex Period 
Observe
d Predicted (95% PI)   Observed Predicted (95% PI) 
Male 
1956-
1960 6,384 7,037 (5,547 - 8,934) 
 
26.9 29.6 (23.3 - 37.5) 
 
1961-
1965 9,377 9,219 (7,277 - 11,684) 
 
36.3 35.6 (28.1 - 45.2) 
 
1966-
1970 12,580 11,697 (9,233 - 14,822) 
 
45.0 41.8 (33.0 - 53.1) 
 
1971-
1975 15,633 15,396 (12,079 - 19,625) 
 
49.9 49.3 (38.6 - 62.9) 
 
1976-
1980 18,628 18,959 (14,817 - 24,262) 
 
53.7 54.6 (42.7 - 69.9) 
 
1981-
1985 21,417 21,243 (16,697 - 27,028) 
 
54.7 54.3 (42.7 - 69.0) 
 
1986-
1990 22,606 22,791 (18,063 - 28,759) 
 
50.5 50.9 (40.3 - 64.2) 
 
1991-
1995 23,213 23,264 (18,616 - 29,075) 
 
45.7 45.8 (36.6 - 57.3) 
 
1996-
2000 23,251 23,250 (18,783 - 28,784) 
 
40.0 40.0 (32.3 - 49.6) 
 
2001-
2005 23,350 23,784 (19,290 - 29,337) 
 
34.7 35.3 (28.6 - 43.6) 
 
2006-
2010 24,128 24,176 (19,614 - 29,820) 
 
30.9 31.0 (25.1 - 38.4) 
 
2011-
2015 24,831 24,450 (19,812 - 30,208) 
 
27.2 26.7 (21.6 - 33.2) 
 
2016-
2020 
 
24,686 (19,898 - 30,680) 
  
23.0 (18.4 - 28.8) 
 
2021-
2025 
 
25,092 (20,034 - 31,502) 
  
20.1 (15.9 - 25.6) 
 
2026-
2030 
 
25,877 (20,382 - 32,950) 
  
18.0 (14.0 - 23.3) 
 
2031-
2035 
 
26,582 (20,596 - 34,416) 
  
16.4 (12.5 - 21.7) 
  
2036-
2040   26,805 (20,396 - 35,330)     15.1 (11.3 - 20.2) 
Total males 
1956-
2040   
354,31
0 
(281,134 
- 
447,216
)           
  Number of deaths   
Age-standardised mortality 
rate 
Sex Period 
Observe
d Predicted (95% PI)   Observed Predicted (95% PI) 
Female 
1956-
1960 990 1,004 (689 - 1,466) 
 
3.7 3.8 (2.6 - 5.5) 
 
1961-
1965 1,336 1,381 (946 - 2,018) 
 
4.5 4.6 (3.2 - 6.8) 
 
1966-
1970 1,950 1,914 (1,312 - 2,793) 
 
5.9 5.8 (4.0 - 8.5) 
 
1971- 2,769 2,779 (1,892 - 4,085) 
 
7.4 7.4 (5.1 - 10.9) 
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1975 
 
1976-
1980 4,111 3,995 (2,697 - 5,919) 
 
9.8 9.5 (6.4 - 14.1) 
 
1981-
1985 5,645 5,598 (3,756 - 8,348) 
 
11.9 11.8 (7.9 - 17.7) 
 
1986-
1990 7,359 7,330 (4,927 - 10,910) 
 
13.7 13.6 (9.2 - 20.3) 
 
1991-
1995 9,178 9,099 (6,144 - 13,481) 
 
15.1 15.0 (10.1 - 22.3) 
 
1996-
2000 10,581 10,818 (7,353 - 15,921) 
 
15.4 15.7 (10.7 - 23.2) 
 
2001-
2005 12,638 12,750 (8,692 - 18,710) 
 
16.1 16.2 (11.0 - 23.8) 
 
2006-
2010 14,770 14,613 (9,980 - 21,427) 
 
16.6 16.3 (11.1 - 24.1) 
 
2011-
2015 16,209 16,403 (11,197 - 24,100) 
 
15.8 16.0 (10.8 - 23.8) 
 
2016-
2020 
 
18,192 (12,378 - 26,861) 
  
15.3 (10.3 - 23.0) 
 
2021-
2025 
 
19,913 (13,465 - 29,663) 
  
14.3 (9.5 - 21.8) 
 
2026-
2030 
 
22,097 (14,788 - 33,348) 
  
13.4 (8.8 - 21.0) 
 
2031-
2035 
 
24,184 (15,833 - 37,449) 
  
12.7 (8.0 - 20.5) 
  
2036-
2040   25,598 (16,280 - 40,946)     11.8 (7.2 - 19.9) 
Total 
females 
1956-
2040   
197,67
0 
(132,330 
- 
297,443
)           
 *Age-standardised mortality rates are standardised to the WHO World Standard Population 
PI: Prediction interval from bootstrap 
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